A Clinical Study To Evaluate The Efficacy Of Kasisadya Vati In The Management Of Chronic Liver Disease W.S.R To Kumbhakamala.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- In Normalizing the Abnormal Liver Enzymes.
研究概览
简要总结
Chronic liver disease is gradually becoming a public health priority in india.Overall Nonalcoholic fatty liver disease(NAFLD) and Alcoholic liver disease(ALD) are emerging as important cases of Chronic liver disease in the country paralleling the changes in lifestyle and social custom. Regional variabilities of Chronic liver disease are evident in this geographically and ethically diverse country. Hepatitis-B still remains the major cause of Chronic liver disease and cancer. As Chronic liver disease can be correlated with Kumbhakamala which is a pittaja nanatmaja vyadhi, Raktapradoshaja vyadhi and Raktavaha srotovyadhi. As Yakrit and Pleeha are moolas of Raktavaha srotas. Hence this clinical trial is initiated to revalidate the efficacy of kasisadya vati in normalizing the liver enzymes and to minimize the alteration of liver parenchymal cells
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Fatty Liver Of Grade 1,2,
- •Liver Parenchymal Changes With Or Without Hyperbilirubinemia .
- •Alcoholic Or Non-Alcoholic Liver Disease.
排除标准
- •Any Viral Infections like Hepatitis-B/A.
- •Hepatorenal Syndrome
- •Hepatopulmonary Syndrome.
- •Hepatic Encephalopathy.
- •Total Bilirubin of Greater than 7mg/dl
- •MELD SCORE Greater than 21
- •Patients who develop Spontaneous Bacterial Peritonitis.
- •Diseases Of Gallbladder/ Suffering from Pancreatitis..
结局指标
主要结局
In Normalizing the Abnormal Liver Enzymes.
时间窗: 90 Days
次要结局
- Reducing the Stiffness Of Liver(90 Days)
研究者
Dr. Chepuri Bhargavi
Dr.BRKR Government Ayurvedic college and hospital.